A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects - Concepedia

Concepedia

Publication | Open Access

A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

DOI Full Paper Access

29

Citations

1

References

2017

Year

Willem Hettema, Christopher Wynne, Benjamin Lang, Mario Altendorfer, Niklas Czeloth, Ragna Lohmann, Sandeep N. Athalye, Dorothee E. Schliephake

Expert Opinion on Investigational Drugs

Abstract

NCT01608087.

References

	Year	Citations

Page 1